Evidence map›Paper›PMID 27069764›Full record

ArticleAmerican journal of nuclear medicine and molecular imaging2016

Bioluminescence imaging of estrogen receptor activity during breast cancer progression.

Cristina Vantaggiato, Giulia Dell'Omo, Balaji Ramachandran, Isabella Manni, Enrico Radaelli, Eugenio Scanziani, Giulia Piaggio, Adriana Maggi, Paolo Ciana

Open access · greenAbstract read
In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Cristina VantaggiatoDepartment of Pharmacological and Biomolecular Sciences, Center of Excellence on Neurodegenerative Diseases, University of Milan 20133, Milan, Italy.
Giulia Dell'OmoDepartment of Pharmacological and Biomolecular Sciences, Center of Excellence on Neurodegenerative Diseases, University of Milan 20133, Milan, Italy.
Balaji RamachandranDepartment of Pharmacological and Biomolecular Sciences, Center of Excellence on Neurodegenerative Diseases, University of Milan 20133, Milan, Italy.
Isabella ManniDepartment of Research, Advanced Diagnostics and Technological Innovation, Regina Elena National Cancer Institute Via Elio Chianesi 53, 00144, Rome, Italy.
Enrico RadaelliMouse & Animal Pathology Lab, Fondazione Filarete Viale Ortles 22/4 - 20139, Milano, Italy.
Eugenio ScanzianiMouse & Animal Pathology Lab, Fondazione Filarete Viale Ortles 22/4 - 20139, Milano, Italy.
Giulia PiaggioDepartment of Research, Advanced Diagnostics and Technological Innovation, Regina Elena National Cancer Institute Via Elio Chianesi 53, 00144, Rome, Italy.
Adriana MaggiDepartment of Pharmacological and Biomolecular Sciences, Center of Excellence on Neurodegenerative Diseases, University of Milan 20133, Milan, Italy.
Paolo CianaDepartment of Pharmacological and Biomolecular Sciences, Center of Excellence on Neurodegenerative Diseases, University of Milan 20133, Milan, Italy.
University of Milan · ITFondazione Filarete · ITNational Cancer Institute · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Estrogen receptors (ER) are known to play an important regulatory role in mammary gland development as well as in its neoplastic transformation. Although several studies highlighted the contribution of ER signaling in the breast transformation, little is known about the dynamics of ER state of activity during carcinogenesis due to the lack of appropriate models for measuring the extent of receptor signaling in time, in the same animal. To this aim, we have developed a reporter mouse model for the non-invasive in vivo imaging of ER activity: the ERE-Luc reporter mouse. ERE-Luc is a transgenic mouse generated with a firefly luciferase (Luc) reporter gene driven by a minimal promoter containing an estrogen responsive element (ERE). This model allows to measure receptor signaling in longitudinal studies by bioluminescence imaging (BLI). Here, we have induced sporadic mammary cancers by treating systemically ERE-Luc reporter mice with DMBA (9,10-dimethyl 1,2-benzanthracene) and measured receptor signaling by in vivo imaging in individual animals from early stage until a clinically palpable tumor appeared in the mouse breast. We showed that DMBA administration induces an increase of bioluminescence in the whole abdominal area 6 h after treatment, the signal rapidly disappears. Several weeks later, strong bioluminescence is observed in the area corresponding to the mammary glands. In vivo and ex vivo imaging analysis demonstrated that this bioluminescent signal is localized in the breast area undergoing neoplastic transformation. We conclude that this non-invasive assay is a novel relevant tool to identify the activation of the ER signaling prior the morphological detection of the neoplastic transformation.

Indexed as

chemical carcinogenesishormone-dependent cancerMammary tumorigenesisoptical imaging

Identifiers

PMID27069764
PMCPMC4749503
OpenAlexW2413849272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.